Speaker Name: Prof. Bryan Williams, Professor, Preventive Cardiology, NUI Galway Consultant Cardiologist, University Hospital Galway, Ireland.

Watch the session to:

• Understand why uncontrolled BP remains common despite treatment and how long-acting therapies may improve adherence.
• Review RNA therapeutics for HTN, including Zilebesiran and findings from the KARDIA clinical trial program.
• Learn how aldosterone synthase inhibitors may improve resistant HTN and cardiometabolic risk linked to high aldosterone.
• Explore natriuretic peptide-based therapies designed to enhance natriuresis, vasodilation, and metabolic effects.
• Gain insight into biologically targeted combination strategies, including novel antihypertensive agents with SGLT2 inhibitors for cardiorenal protection.